The ICH guidance in practice: Stress degradation studies on stavudine and development of a validated specific stability-indicating HPTLC assay method

Journal of Chromatographic Science

Volumn 43, Issue 8, 2005, Pages 406-415

  Kaul, Neeraj ^a   Agrawal, Himani ^a   Paradkar, Anant Raghunath ^a   Mahadik, Kakasaheb Ramoo ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27644457016     PISSN: 00219665     EISSN: 00219665     Source Type: Journal    
DOI: 10.1093/chromsci/43.8.406     Document Type: Article

References (45)

1. M.J.M. Hitchcock. Review: antiviral portrait series, no. 1, 2% 3% - didehydro 2% 3% - dideoxy thymidine (d4T) an anti HIV agent. Antivir. Chem. Chemother. 2: 125-32 (1991).
2. S. Kaul, L. Dunkle, R. Anderson, C. McLaren, A. Cross, M. Brown, R. Gugliotti, and M. Adler. Program of Abstracts. VIII International Conference AIDS, Amsterdam, the Netherlands, Abstract WeB 1011: 19-24 (1992).
3. E. Peterson, C. Ramirez-Ronda, R. Schwartz, D. Peterson, W. Hardy, H. Sacks, and S. Follansbee. Program of Abstracts. VIII International Conference AIDS, Amsterdam, the Netherlands, Abstract PoB 3023: 19-24 (1992).
4. S. Kaul, N.M. Dudley, K.K. Graham, S. Geletko, L. Dunkle, M. Browne, and K. Mayer. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166: 480-85 (1992).
5. E.M. Connor, R.S. Sperling, R. Gelber, P. Kiselev, and G. Scott. Reduction of maternal infant transmission of human immunodeficiency virus type1 with zidovudine treatment. N. Engl. J. Med. 331: 1173-80 (1994).
6. G.B. Scott, C. Hutto, R.W. Makuch, M.T. Mastrucci, T.O. Connor, C.D. Mitchell, E.J. Trapido, and W.P. Parks. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. J. Infect. Dis. 321: 1791-96 (1989).
7. R.B. Van Dyke, B.T. Korber, E. Popek, C. Macken, and S.M. Widmayer. The Ariel Project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J. Infect. Dis. 179: 319-28 (1999).
8. L.A. Guay, P. Musoke, T. Fleming, D. Bagenda, and M. Allen. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet 354: 795-802 (1999).
9. R.D. Keller, C. Nosbisch, and J.D. Unadkat. In vivo maternal-fetal pharmacokinetics of stavudine in pig tailed macaques. Antimicrob. Agents Chemother. 40: 196-202 (1996).
10. S. Kaul, M.W. Kline, J.A. Church, and L.M. Dunkle. Determination of dosing guidelines for stavudine (2′,3′-didehydro-3′- deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 45: 758-63 (2001).
11. S. Kaul, M.W. Kline, L.M. Dunkle, A.T. Harris, M.E. Federici, H.M. Rosenblatt, I.C. Hanson, and W.T. Shearer. Program of Abstracts. 1st National Conference Human Retro Viruses, Washington, D.C., Abstract 585: (1993).
12. D.M. Burger, H. Rosing, R.V. Gijn, P.L. Meenhorst, O.V. Tellingen, and J.H. Beijnen. Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 584: 239-47 (1992).
13. S. Kaul, J.S. Janiszewski, D.E. Mulvana, K.A. Dandenkar, and R.H. Barbhaiya. High-performance liquid chromatographic determination of 2′,3′-didehydro-3′-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine. J. Chromatogr. 577: 151-56 (1992).
14. C.M. Riley, J.M. Ault, Jr., and N.E. Klutman. Chromatographic methods for the bioanalysis of antiviral agents. J. Chromatogr. 531: 295-368 (1990).
15. A. DeLean, P.J. Munson, and D. Rodbard. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235: E97-E102 (1978).
16. S. Kaul, B. Stouffer, V. Mummaneni, N. Turabi, S. Mantha, P. Jayatilak, and R. Barbhaiya. Specific radioimmunoassays for the measurement of stavudine in human plasma and urine. J. Pharm. Biomed Anal. 15: 165-74 (1996).
17. S.R. Brody and F.T. Aweeka. Pharmacokinetics of intracellular zidovudine and its phosphorylated anabolites in the absence and presence of stavudine using an in vitro human peripheral blood mononuclear cell (PBMC) model. Int. J. Antimicrob. Agents 9: 131-35 (1997).
18. M. Sarasa, N. Riba, L. Zamora, and X. Carne. Determination of stavudine in human plasma and urine by high performance liquid chromatography using a reduced sample volume. J. Chromatogr. B 746: 183-89 (2000).
19. J.L. Wiesner, F.C.W. Sutherland, M.J. Smit, G.H. Van Essen, H.K.L. Hundt, K.J. Swart, and A.F. Hundt. Sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of stavudine in human plasma. J. Chromatogr. B 773: 129-34 (2002).
20. T.T. Tran, B.L. Robbins, F.H. Pinkerton, B. Ferrua, J. Grassi, and A. Fridland. A new sensitive cartridge-RIA method for determination of stavudine (D4T) triphosphate in human cells in vivo. Antiviral Res. 58: 125-29 (2003).
21. V.A. Simon, M.D. Thiam, and L.C. Lipford. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high performance liquid chromatography. J. Chromatogr. A 913: 447-53 (2001).
22. J.D. Moore, G. Valette, and A. Darque. Simultaneous quantitation of the 5*-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 11: 1134-43 (2000).
23. S. Kiippers, B. Lorenschaft, F.P. Schmitz, and E. Klesper. Determination of stavudine by high performance liquid chromatography. J. Chromatogr. 475: 85-92 (1989).
24. ICH, Q1A. Stability testing of new drug substances and products. International Conference on Harmonization, Geneva, Switzerland, October, 1993.
25. K. Ferenczi-Fodor, Z. Vigh, and Z. Pap-Sziklay. Validation of the quantitative planar chromatographic analysis of drug substances. J. Planar Chromatogr. 6: 198-203 (1993).
26. K. Ferenczi-Fodor, Z. Vigh, A. Nagy-Turak, B. Renger, and M. Zeller. Validation and quality assurance of planar chromatography procedures in pharmaceutical analysis. J. AOAC Int. 84: 1265-76 (2001).
27. K. Ferenczi-Fodor and Z. Vigh. Planar Chromatography-A Retrospective View from the Third Millennium. Sz. Nyiredy, Ed. Springer Scientific Publisher, Budapest, Hungary, 2001, pp. 336-52.
28. European Pharmacopoeia, In. 3rd ed. Council of Europe, Strasbourg, France, 1997, p. 963.
29. European Pharmacopoeia, 3rd ed. Suppl. Council of Europe, Strasbourg, France, 1999, pp. 5-7.
30. Thin layer chromatography, Monograph 2.2.27. European Pharmacopoeia, Council of Europe, Strasbourg, France, 2002, p. 3638.
31. L. W. Doner. Determining sugar composition of food gum polysaccharides by HPTLC. Chromatographia 53: 579-88 (2001).
32. J. Sherma and B. Fried. Handbook of Thin-Layer Chromatography, 2nd ed. Marcel Dekker, New York, 1996, pp. 129-148,273-306.
33. B. Renger. Contemporary thin layer chromatography in pharmaceutical quality control. J. AOAC Int. 81: 333-40 (1998).
34. G.W. Ponder and J.T. Stewart. High-performance thin-layer chromatographic determination of digoxin and related compounds, digoxigenin bisdigitoxoside and gitoxin, in digoxin drug substance and tablets. J. Chromatogr. A 659: 177-83 (1994).
35. C. Weins and H.E. Hauck. Advances and developments in thin layer chromatography. LC-GC 14: 456-64 (1996).
36. K.E. McCarthy, Q. Wang, E.W. Tsai, R.E. Gilbert, and M.A. Brooks. Determination of losartan and its degradates in Cozaar tablets by reversed-phase high-performance thin-layer chromatography. J. Pharm. Biomed. Anal. 17: 671-77 (1998).
37. S.E. Jovanovic, D. Agbaba, D. Zivanov-Stakic, and S. Vladimirov. HPTLC determination of ceftriaxone, cefixime and cefotaxime in dosage forms. J. Pharm. Biomed. Anal. 18: 893-98 (1998).
38. ICH, Q2A. "Validation of Analytical Procedure: Methodology". International Conference on Harmonization, Geneva, Switzerland, October 1994.
39. ICH, Q2B. Validation of analytical procedure: methodology. International Conference on Harmonization, Geneva, Switzerland, March 1996.
40. ICH. Guidance on analytical method validation. International Convention on Quality for the Pharmaceutical Industry, Toronto, Canada, September 2002.
41. P.D. Sethi. High Performance Thin Layer Chromatography, Quantitative Analysis of Pharmaceutical Formulations. CBS Publishers and Distributors, New Delhi, India, 1996.
42. E.R. Garrett and R.F. Carper. Chemical stability of pharmaceuticals. J. Am. Pharm. Assoc. Sci. 44: 515-21 (1955).
43. J.T. Carstensen and C.T. Rhodes. Drug Stability: Principles and Practices, 3rd ed. Marcel Dekker, New York, NY, 2000.
44. P.M. Schyve and J.A. Prevost, From quality assurance to quality improvement Psychiatr. Clin. North Am. 13: 61-67 (1990).
45. Y. Xiang and B. Wang. The principles of quantification in scanning thin-layer chromatography. Chin. J. Univ. Chem. 8: 34-38 (1993).